Warnecke Athanasia, Averbeck Thomas, Wurster Ulrich, Harmening Meike, Lenarz Thomas, Stöver Timo
Departments of Otorhinolaryngology and Neurology, Medical University of Hannover, Hannover, Germany.
Arch Otolaryngol Head Neck Surg. 2004 Oct;130(10):1178-84. doi: 10.1001/archotol.130.10.1178.
The beta(2)-transferrin assay is a specific method to identify cerebrospinal fluid (CSF). Hitherto, this test has not been widely used for the routine screening of patients with suspected CSF leakage. The purpose of this study was to investigate the clinical relevance of the identification of beta(2)-transferrin by comparing the test results with other diagnostic measures and intraoperative findings.
Case series.
Retrospective analysis of 182 patients tested once or multiple times for beta(2)-transferrin.
Information was obtained regarding different diagnostic procedures applied to diagnose CSF leakage. The effectiveness of those diagnostic measures was compared.
The main indication to test for beta(2)-transferrin was posttraumatic rhinorrhea (25%), followed by spontaneous (22%) and postsurgical (22%) rhinorrhea. In 35 of 205 cases, beta(2)-transferrin was detected in the tested specimens. Thirteen of these required surgical intervention for treatment of the CSF fistula, and the leakage site was identified in all of them. Taking all results into consideration, the highest correlation was observed between the beta(2)-transferrin assay, intrathecal fluorescein application, and surgical exploration.
The beta(2)-transferrin assay is a reliable method for confirming suspected CSF and should be used as a primary screening method in all patients with suspected CSF leakage. Although less invasive, the beta(2)-transferrin assay almost matches the high sensitivity achieved by exploratory surgery and intrathecal application of fluorescein. However, the possibility of bias should be carefully considered, and in particular, negative results should be critically compared with clinical symptoms and with results from other diagnostic procedures.
β2-转铁蛋白检测是一种识别脑脊液(CSF)的特异性方法。迄今为止,该检测尚未广泛用于疑似脑脊液漏患者的常规筛查。本研究的目的是通过将检测结果与其他诊断方法及术中发现进行比较,探讨β2-转铁蛋白检测的临床相关性。
病例系列研究。
对182例接受过一次或多次β2-转铁蛋白检测的患者进行回顾性分析。
获取有关用于诊断脑脊液漏的不同诊断程序的信息。比较这些诊断措施的有效性。
检测β2-转铁蛋白的主要指征是创伤后鼻漏(25%),其次是自发性鼻漏(22%)和术后鼻漏(22%)。在205例病例中,有35例检测标本中检测到β2-转铁蛋白。其中13例需要手术干预治疗脑脊液瘘,且均确定了漏口位置。综合所有结果来看,β2-转铁蛋白检测、鞘内注射荧光素及手术探查之间的相关性最高。
β2-转铁蛋白检测是确诊疑似脑脊液漏的可靠方法,应用于所有疑似脑脊液漏患者的初步筛查。尽管侵入性较小,但β2-转铁蛋白检测几乎可达到与探查手术及鞘内注射荧光素相同的高灵敏度。然而,应仔细考虑偏倚的可能性,尤其是对于阴性结果,应与临床症状及其他诊断程序的结果进行严格比较。